New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis November 9, 2019 New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis Vectra Test Predicts Radiographic Progression an... Continue Reading
Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting November 1, 2019 Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting SALT LAKE CITY, Nov. 01, 2019 (GLOBE NEWSWIRE) -- M... Continue Reading
Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting October 28, 2019 Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting SALT LAKE CITY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Myr... Continue Reading
Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting October 8, 2019 Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting SALT LAKE CITY, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Myriad G... Continue Reading
Myriad Announces Research Collaboration with University of Leeds September 16, 2019 Myriad Announces Research Collaboration with University of Leeds Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer SALT LAKE ... Continue Reading
Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment September 5, 2019 Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment 65 Percent of Patients Remained on Active Surveillance for More than Four Yea... Continue Reading
Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention August 22, 2019 Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention More Women May Benefit from Hereditary Cancer Risk Ass... Continue Reading
Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer August 7, 2019 Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cance... Continue Reading
Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer June 27, 2019 Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer Validation Study Shows Prolaris Test Identifies Men Who M... Continue Reading
BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer June 24, 2019 BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Sta... Continue Reading